10-Q: Astrana Health Reports Third Quarter 2024 Results, Revenue Jumps 37%

Astrana Health's third quarter 2024 results show a significant 37% increase in revenue, driven primarily by capitation growth and recent acquisitions.

Summary

• Astrana Health's third quarter 2024 revenue reached $478.7 million, a 37% increase compared to the same period last year.
• The revenue growth was primarily fueled by a $125.7 million increase in capitation revenue, resulting from recent acquisitions and enrollees transitioning to full risk.
• Operating expenses also increased, with cost of services rising by $129.8 million to $405.2 million.
• General and administrative expenses increased by $8.4 million to $37.8 million.
• Depreciation and amortization expenses rose by $3.0 million to $7.3 million.
• The company's net income attributable to Astrana Health, Inc. decreased to $16.1 million, compared to $22.1 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, total revenue was $1,369.3 million, a 32% increase year-over-year.
• Net income attributable to Astrana Health, Inc. for the nine months was $50.1 million, a slight increase from $48.4 million in the same period of 2023.
• The company is raising its revenue guidance and narrowing its net income attributable to Astrana, Adjusted EBITDA, and EPS guidance for the year ending December 31, 2024.
• The company now expects total revenue between $1.95 billion and $2.03 billion, net income attributable to Astrana between $52 million and $58 million, and Adjusted EBITDA between $165 million and $175 million.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong, the decrease in net income and increased expenses raise concerns. The potential acquisition and associated debt also add uncertainty. The sentiment is cautiously optimistic.

Positives

• Significant revenue growth driven by capitation and acquisitions.
• Increase in the number of patients managed by the company.
• The company is raising its revenue guidance and narrowing its net income attributable to Astrana, Adjusted EBITDA, and EPS guidance for the year ending December 31, 2024.

Negatives

• Net income attributable to Astrana Health, Inc. decreased in the third quarter.
• Operating expenses increased significantly, particularly cost of services.
• Interest expense increased due to greater amounts borrowed on the Amended Credit Facility.

Risks

• The company's performance is subject to regulatory risks and changes in healthcare laws.
• The company's financial results are subject to estimates and assumptions, which may differ from actual results.
• The company's debt levels have increased, which could impact financial flexibility.
• The company's ability to successfully integrate acquisitions may impact future performance.
• The company's ability to complete the proposed acquisition of Prospect Medical Holdings is subject to conditions and may not be completed on a timely basis, or at all.

Future Outlook

The company is raising its revenue guidance and narrowing its net income attributable to Astrana, Adjusted EBITDA, and EPS guidance for the year ending December 31, 2024. The company now expects total revenue between $1.95 billion and $2.03 billion, net income attributable to Astrana between $52 million and $58 million, and Adjusted EBITDA between $165 million and $175 million.

Industry Context

The company's focus on value-based care and provider-centric models aligns with broader industry trends towards more efficient and coordinated healthcare delivery. The company's participation in the ACO REACH Model and MSSP also reflects the industry's shift towards risk-sharing arrangements.

Comparison to Industry Standards

• The company's revenue growth of 37% in the third quarter is significantly higher than the average growth rate for healthcare companies, which is typically in the single-digit range.
• The company's focus on acquisitions and expansion into new markets is a common strategy among healthcare companies looking to increase market share and revenue.
• The company's Adjusted EBITDA margin of 10% for the nine months ended September 30, 2024, is within the typical range for healthcare companies, but there is room for improvement.
• The company's debt levels are higher than some of its peers, which could impact its financial flexibility.
• The company's participation in the ACO REACH Model and MSSP is in line with industry trends towards value-based care, but the company's performance in these programs will need to be monitored closely.

Related Party Transactions

• The company has various related-party transactions, including management fees, provider services, rent expenses, and other services with entities that share common ownership or have board members in common.
• The company has a risk-sharing agreement with AHMC hospitals to share the surplus and deficits of each of the hospital pools.

Stakeholder Impact

• Shareholders may be concerned about the decrease in net income despite revenue growth.
• Employees may be impacted by the integration of recent acquisitions.
• Customers may benefit from the company's expansion and increased service offerings.
• Suppliers may see increased business opportunities due to the company's growth.
• Creditors may be impacted by the company's increased debt levels.

Next Steps

• The company will continue to integrate recent acquisitions.
• The company will focus on managing expenses and improving profitability.
• The company will work towards completing the proposed acquisition of Prospect Medical Holdings, Inc.
• The company will continue to participate in the ACO REACH Model and MSSP.

Key Dates

Keywords

capitation, healthcare, acquisitions, revenue, EBITDA, risk-bearing, Medicare, Medicaid, financial results, operating expenses